Global Acquired Haemophilia Therapeutics Market- Industry Analysis- By Therapy TPosted by rahul on February 20th, 2021
Acquired Haemophilia is a rare genetic disorder, which is characterized by bleeding that occurs in patients with a negative personal or family history for haemorrhages. Autoimmune disorders occur when the body’s immune system mistakenly attacks healthy cells or tissue. In Acquired Haemophilia (AH), the body produces antibodies that attack clotting factors. Clotting factors are specialized proteins required for the blood to clot normally. The treatment of Haemophilia comprises two approaches- To control bleeding episodes and other is to reduce inhibitor titer against clotting factor VIII in blood serum. To counter these blood complications, physicians prefer therapeutic drugs such as Desmopressin and Obizur. Increasing geriatric population and exceptional drug pharmacodynamic and pharmacokinetic profile shown by the immunomodulatory therapy are key drivers for the AH therapeutics market growth. Promising results showed up by the immunomodulatory agents in phase III clinical trials, will increase its demand as the first-line drug therapy to reduce the inhibitors pertaining to clotting factor VIII in the blood serum. However, the high costs associated with the bypassing agents used to control bleeding episodes may hamper market growth. The report covers the detailed analysis of global Acquired Haemophilia Therapeutics Market with the classifications of the market based on therapy type, Distribution channels, and region. Analysis of past market dynamics from 2016 to 2019 is given in the report, which will help readers to benchmark the past trends with current market scenarios with the key players contribution in it. The report has profiled fourteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques. Report has come up with recommendations for future hot spot in APAC region. New research findings, funding policies for projects and its impact on AH Therapeutics market are covered ion the report. Segment Analysis The advanced therapy segment is expected to grow because of advanced tests which are performed often. The first step in AH is to control bleeding, which is done by injecting blood clotting factors. The bypassing agents for this include Activated Factor VII (NovoSevenRT) or Activated Prothrombin Complex Concentrates (aPCC). Hence, as the first line of treatment, these therapeutics are increasing market growth. The market for advanced therapies is expected to grow by $XX Mn in the forecast period. Global Acquired Haemophilia Therapeutics Market Market Segmentation The global Acquired Haemophilia Therapeutics Market is classified by- Therapy type • Traditional Therapy • Advanced Therapy Desmopressin Distribution Channels • Hospital Pharmacies Regional Insights Global Acquired Haemophilia Therapeutics Market1 North America is currently dominating the Acquired Haemophilia Therapeutics Market. The factors responsible for market growth are increasing public health awareness regarding autoimmune diseases, which is leading to early diagnosis and treatment. Affordable reimbursement policies for treating acquired haemophilia is expected to strengthen the market growth in this region. Europe represents a market share of 31%, the reason being the presence of key companies such as Baxter Healthcare Corporation, GlaxoSmithKline, Shire Plc and Novo Nordisk in this region. Asia Pacific holds 16% of market share and is expected to grow by $XX Mn during the forecast period. The rising prevalence of acquired haemophilia and developing healthcare infrastructure are contributing to market growth. • Biogen, Inc About Us: Maximize Market Research provides B2B and B2C market research on Like it? Share it! More by this author |